Related Experiment Videos
Antiendotoxin therapies for septic shock
1Critical Care Department, Children's National Medical Center, Washington, D.C.
Infectious Agents and Disease
|February 1, 1993
Summary
Despite decades of research, anti-endotoxin therapies for Gram-negative shock have not proven effective in humans. Newer agents may still offer therapeutic benefits for septic shock patients.
Area of Science:
- Microbiology
- Immunology
- Critical Care Medicine
Background:
- Gram-negative shock is primarily attributed to bacterial endotoxin.
- Extensive research has focused on anti-endotoxin therapies for over 30 years.
- No anti-endotoxin treatment has demonstrated proven benefit for human septic shock.
Purpose of the Study:
- To evaluate the efficacy of anti-endotoxin therapies in Gram-negative shock.
- To analyze the outcomes of recent clinical trials involving monoclonal antibodies against endotoxin.
- To explore the potential of novel anti-endotoxin agents for septic shock treatment.
Main Methods:
- Review of randomized clinical trials of monoclonal antibodies against endotoxin.
- Assessment of endotoxin neutralization in vitro.
- Evaluation of protective effects in animal models of sepsis.
Main Results:
- Recent clinical trials did not convincingly demonstrate therapeutic efficacy of monoclonal antibodies.
- Antibodies used in trials showed limited in vitro endotoxin neutralization.
- These antibodies were not consistently protective in animal sepsis models.
Conclusions:
- Current anti-endotoxin therapies, including specific monoclonal antibodies, have not proven effective for human septic shock.
- The failure of these antibodies does not preclude the success of other anti-endotoxin strategies.
- Novel agents with defined anti-endotoxin mechanisms may clarify endotoxin's role and offer future therapeutic options for septic shock.